Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of the study is to evaluate the effect of CPAP over the incidence of cardiovascular events and diagnosis of arterial hypertension in patients with sleep apnea.
The hypothesis of the study is the following: The existence of sleep disordered breathing in the general population is associated to an increased incidence of arterial hypertension and to an increased risk of suffering cardiovascular disease. CPAP corrects respiratory disorders during sleep. Treatment with CPAP in subjects with sleep disordered breathing without daytime sleepiness reduces the incidence of systemic arterial hypertension and cardiovascular complications.
The end points of the study are new diagnosis of arterial hypertension and new cardiovascular events.
All patients, after randomization, will be followed for three years.
| Condition | Intervention | Phase |
|---|---|---|
|
Sleep Apnea Hypertension Cardiovascular Diseases |
Device: CPAP (Continuous Positive Airway Pressure) |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Effect of CPAP on Arterial Hypertension and Cardiovascular Morbi-Mortality in Patients With Sleep Apnea and Without Daytime Sleepiness |
- Incidence of hypertension
- Incidence of cardiovascular events
- Relationship between hypertension and sleep apnea/hypopnea syndrome (SAHS) severity
- Relationship between cardiovascular events and SAHS severity
| Estimated Enrollment: | 700 |
| Study Start Date: | May 2004 |
| Estimated Study Completion Date: | April 2006 |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Epworth <10
- Apnea-Hypopnea Index ≥20
Exclusion Criteria:
- Presence of any chronic disease
- Presence of cardiovascular disease
- Refusal to sign informed consent
- Drug addiction and/or alcoholism
Contacts and Locations| Spain | |
| Hospital Univ Arnau de Vilanova | |
| Lleida, Catalonia, Spain, 25198 | |
| Principal Investigator: | Ferran Barbe, MD | Hospital Universitari Arnau de Vilanova. Lleida. Spain |
More Information
No publications provided by Sociedad Española de Neumología y Cirugía Torácica
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00127348 History of Changes |
| Other Study ID Numbers: | PI 040165 |
| Study First Received: | August 4, 2005 |
| Last Updated: | April 2, 2007 |
| Health Authority: | Spain: Ministry of Health and Consumption |
Additional relevant MeSH terms:
|
Apnea Cardiovascular Diseases Hypertension Sleep Apnea Syndromes Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |
Signs and Symptoms Vascular Diseases Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013